Back to Business

Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

Business September 30, 2026 at 11:42 PM

Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

Seeking Alpha

Read the full story at Seeking Alpha

More Stories

PSCI: SMID Industrials Are Likely To Trail IVV Amid Higher Rates

PSCI: SMID Industrials Are Likely To Trail IVV Amid Higher Rates

🇺🇸 Seeking Alpha 5m ago

Japan business mood improves, tankan survey shows

Japan business mood improves, tankan survey shows

🇺🇸 Investing.com 14m ago

BOJ debated need for more rate hikes at September meeting, summary shows

BOJ debated need for more rate hikes at September meeting, summary shows

🇺🇸 Investing.com 15m ago

Your world briefing, in your pocket

Curated news from 12 countries and 10 languages. Coming soon on iOS and Android.

Coming soon on App Store Coming soon on Google Play